Restricted accessResearch articleFirst published online 2015-01
Early Interaction of Adeno-Associated Virus Serotype 8 Vector with the Host Immune System Following Intramuscular Delivery Results in Weak but Detectable Lymphocyte and Dendritic Cell Transduction
Following in vivo recombinant adeno-associated virus (rAAV)–based gene transfer, adaptive immune responses specific to the vector or the transgene product have emerged as a potential roadblock to successful clinical translation. The occurrence of such responses depends on several parameters, including the route of vector administration as well as the viral serotype and the genome configuration, either self-complementary (sc) or single-stranded (ss). These parameters influence rAAV vector-associated immunity by modulating the crosstalk between the vector and the host immune system, including vector ability to interact or even transduce lymphoid tissues in general and antigen-presenting cells (APCs) in particular. Little is known about immune cell populations that are targeted in vivo by rAAV vectors. Moreover, the transduction of dendritic cells is still controversial and not directly demonstrated. Here, we show that intramuscular administration of an sc rAAV8 vector in the mouse leads to a rapid distribution of viral genomes in the lymphoid tissues that is associated with transgene expression. Transduced cells were detected in follicular areas of the spleen and the draining lymph nodes. In addition to B and T lymphocytes, transduced professional APCs were detected although at very low frequency. In addition, viral genomes and transgene transcripts were also detected in these cell populations after ss rAAV8 vector administration. Although the functional significance of those observations needs further explorations, our results highlight an early and intricate interaction between the rAAV vector upon its in vivo delivery and the host immune system.
Get full access to this article
View all access options for this article.
References
1.
RiveraVM, GaoGP, GrantRL, et al.Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood, 2005; 105:1424–1430.
2.
StiegerK, Le MeurG, LasneF, et al.Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther, 2006; 13:967–975.
3.
WarringtonKHJr., and HerzogRW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet, 2006; 119:571–603.
4.
NiemeyerGP, HerzogRW, MountJ, et al.Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, 2009; 113:797–806.
5.
HerzogRW, MountJD, ArrudaVR, et al.Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther, 2001; 4:192–200.
6.
FavreD, BlouinV, ProvostN, et al.Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol, 2002; 76:11605–11611.
7.
ChenuaudP, LarcherT, RabinowitzJE, et al.Autoimmune anemia in macaques following erythropoietin gene therapy. Blood, 2004; 103:3303–3304.
8.
GaoG, LebherzC, WeinerDJ, et al.Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood, 2004; 103:3300–3302.
9.
RossCJ, TwiskJ, BakkerAC, et al.Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447×beneficial mutation. Hum Gene Ther, 2006; 17:487–499.
10.
MingozziF, MausMV, HuiDJ, et al.CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med, 2007; 13:419–422.
11.
MingozziF, MeulenbergJJ, HuiDJ, et al.AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 2009; 114:2077–2086.
12.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
13.
MartinoAT, SuzukiM, MarkusicDM, et al.The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood, 2011; 117:6459–6468.
14.
RogersGL, MartinoAT, ZolotukhinI, et al.Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med, 2014; 12:25.
15.
MingozziF, LiuYL, DobrzynskiE, et al.Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest, 2003; 111:1347–1356.
16.
MingozziF, HasbrouckNC, Basner-TschakarjanE, et al.Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007; 110:2334–2341.
17.
ToromanoffA, AdjaliO, LarcherT, et al.Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther, 2010; 18:151–160.
18.
FavreD, ProvostN, BlouinV, et al.Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther, 2001; 4:559–566.
19.
ArrudaVR, SchuettrumpfJ, HerzogRW, et al.Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood, 2004; 103:85–92.
20.
WangL, CaoO, SwalmB, et al.Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther, 2005; 12:1453–1464.
21.
WangL, CalcedoR, BellP, et al.Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther, 2011; 22:1389–1401.
22.
ToromanoffA, CherelY, GuilbaudM, et al.Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther, 2008; 16:1291–1299.
23.
HaurigotV, MingozziF, BuchlisG, et al.Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther, 2010; 18:1318–1329.
24.
PonnazhaganS, MahendraG, CurielDT, et al.Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol, 2001; 75:9493–9501.
25.
LiuY, Chiriva-InternatiM, YouC, et al.Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther, 2005; 12:304–312.
26.
AldrichWA, RenC, WhiteAF, et al.Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther, 2006; 13:29–39.
27.
XinKQ, MizukamiH, UrabeM, et al.Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol, 2006; 80:11899–11910.
28.
VeronP, AlloV, RiviereC, et al.Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol, 2007; 81:5385–5394.
29.
OhshimaS, ShinJH, YuasaK, et al.Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther, 2009; 17:73–80.
30.
WuT, TopferK, LinSW, et al.Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther, 2012; 20:572–579.
31.
JoossK, YangY, FisherKJ, et al.Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol, 1998; 72:4212–4223.
32.
ZhangY, ChirmuleN, GaoG, et al.CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol, 2000; 74:8003–8010.
33.
XuD, and WalkerCM. Continuous CD8(+) T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery. J Virol, 2011; 85:12083–12086.
34.
BoisgeraultF, GrossDA, FerrandM, et al.Prolonged gene expression in muscle is achieved without active immune tolerance using MicrorRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther, 2013; 24:393–405.
LuY, and SongS. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A, 2009; 106:17158–17162.
37.
MaysLE, WangL, LinJ, et al.AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion and minimal MHCI upregulation on target cells. Mol Ther, 2013; 22:28–41.
38.
WangZ, ZhuT, QiaoC, et al.Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol, 2005; 23:321–328.
39.
GowansJL. The recirculation of lymphocytes from blood to lymph in the rat. J Physiol, 1959; 146:54–69.
40.
MandlJN, LiouR, KlauschenF, et al.Quantification of lymph node transit times reveals differences in antigen surveillance strategies of naive CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A, 2012; 109:18036–18041.
41.
MasopustD, and SchenkelJM. The integration of T cell migration, differentiation and function. Nat Rev Immunol, 2013; 13:309–320.
42.
WestermannJ, PersinS, MatyasJ, et al.IFN-gamma influences the migration of thoracic duct B and T lymphocyte subsets in vivo. Random increase in disappearance from the blood and differential decrease in reappearance in the lymph. J Immunol, 1993; 150:3843–3852.
43.
BlaschkeV, MicheelB, PabstR, et al.Lymphocyte traffic through lymph nodes and Peyer's patches of the rat: B- and T-cell-specific migration patterns within the tissue, and their dependence on splenic tissue. Cell Tissue Res, 1995; 282:377–386.
44.
CaseSS, PriceMA, JordanCT, et al.Stable transduction of quiescent CD34(+)CD38(−) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A, 1999; 96:2988–2993.
45.
MiyoshiH, SmithKA, MosierDE, et al.Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science, 1999; 283:682–686.
46.
AnDS, WerstoRP, AgricolaBA, et al.Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol, 2000; 74:1286–1295.
47.
SalmonP, KindlerV, DucreyO, et al.High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood, 2000; 96:3392–3398.
48.
ZaissAK, CotterMJ, WhiteLR, et al.Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol, 2008; 82:2727–2740.
49.
ZaissAK, and MuruveDA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther, 2008; 15:808–816.
50.
ChenH, LilleyCE, YuQ, et al.APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol, 2006; 16:480–485.
51.
McCartyDM, MonahanPE, and SamulskiRJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 2001; 8:1248–1254.
52.
CunninghamEC, SharlandAF, BishopGA. Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect?. Clin Dev Immunol, 2013; 2013:419692.
53.
MountJD, HerzogRW, TillsonDM, et al.Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002; 99:2670–2676.
54.
DobrzynskiE, FitzgeraldJC, CaoO, et al.Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A, 2006; 103:4592–4597.
55.
AsokanA, JohnsonJS, LiC, et al.Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther, 2008; 15:1618–1622.
56.
DavidoffAM, GrayJT, NgCY, et al.Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther, 2005; 11:875–888.
57.
NakaiH, WuX, FuessS, et al.Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol, 2005; 79:3606–3614.
58.
GrahamT, McIntoshJ, WorkLM, et al.Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genet Vaccines Ther, 2008; 6:9.
59.
AnguelaXM, TafuroS, RocaC, et al.Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice. Diabetes, 2013; 62:551–560.
60.
AnnoniA, BrownBD, CantoreA, et al.In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood, 2009; 114:5152–5161.
61.
SharlandA, LoganGJ, BishopA, et al.Liver-directed gene expression using recombinant AAV 2/8 vectors—a tolerogenic strategy for gene delivery?. Discov Med, 2010; 9:519–527.
62.
SarukhanA, CamugliS, GjataB, et al.Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol, 2001; 75:269–277.
63.
PorgadorA, SnyderD, and GilboaE. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol, 1996; 156:2918–2926.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
